3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
7
Rectal Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Neoplasm, Residual
2
Mesothelioma, Malignant
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Sarcopenia
1
Sarcoglycanopathies
1
Peritoneal Neoplasms
1
Pancreatic Neuroendocrine Tumors (pNET)
1
Pancreatic Neoplasms
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Mesothelioma
1
Melanoma
1
Malnutrition
1
Lung Neoplasms
1
HER2 Negative Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Frailty
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Temozolomide
15
Radiotherapy
10
Radiation
8
Magnetic Resonance Spectroscopy
7
pembrolizumab
5
Specimen Handling
5
Ipilimumab
3
atezolizumab
2
Photons
2
Nivolumab
2
Biopsy
2
veliparib
1
selinexor
1
sargramostim
1
plerixafor
1
peposertib
1
pazopanib
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
montanide ISA 51
1
liposomal doxorubicin
1
gosha-jinki-gan
1
fluorodopa F 18
1
ferric pyrophosphate
1
efineptakin alfa
1
cemiplimab
1
cabozantinib
1
balstilimab
1
abexinostat
1
X-Rays
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Chemotherapy, Adjuvant
×
1 year
×
Clear all
No trials found.